USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: CHANTEST, INC.
City: CLEVELAND
State: OH
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (216) 332-1665

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $487,784.00 5
SBIR Phase II $1,764,756.00 2

Award List:

NOVEL SIMPLE SCREEN FOR POTASSIUM CHANNELS

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lacerda, Antonio E
Award Amount: $89,263.00

New drugs for treatment of atrial fibrillation

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Antonio E. Lacerda
Award Amount: $99,924.00
Abstract:
Atrial fibrillation (AF) is the commonest cardiac arrhythmia and in its chronic form affects more than two million patients in the USA. AF is associated with cardiac and non-cardiac diseases. About 10% of cases have no obvious cause (lone AF). Stroke is the commonest complication with a 25% greater… More

New drugs for treatment of atrial fibrillation

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Antonio E. Lacerda
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present, there is no satisfactory treatment of this disease. The ChanTest Phase I SBIR was directed towards… More

New drugs for treatment of atrial fibrillation

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Antonio E. Lacerda
Award Amount: $580,448.00
Abstract:
DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present, there is no satisfactory treatment of this disease. The ChanTest Phase I SBIR was directed towards… More

Development of a Complete Proarrhythmic Safety Profile for Drugs

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: James W. Kramer
Award Amount: $149,322.00
Abstract:
DESCRIPTION (provided by applicant): ChanTest's goal is to commercialize a comprehensive non-clinical proarrhythmic profile that will screen compounds through a battery of models that span from the molecular (ion channels) to the multicellular (Purkinje fibers) to whole organ (Langendorff perfused… More

Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrew H. Brueningwright
Award Amount: $149,275.00
Abstract:
DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently characterized a population of SC-hCMs that will be made commer cially available in 2010 by our… More

Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Andrew H. Bruening-wright – 503-494-7732
Award Amount: $1,184,308.00
Abstract:
DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre- clinical cardiac safety testing. We have characterized a population of SC-hCMs and have demonstrated that these cells show sensitive pharmacology that… More